

CONTENTS

	The Platinum Hall of Fame http://dx.doi.10.1016/j.eururo.2019.08.008	e85
Platinum Opinions	Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question <i>M. Varma, B. Delahunt, T. van der Kwast</i>	413
	Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. <i>E. Compe'rat, M. Amin, V. Reute</i>	416
Brief Correspondence	Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone <i>E. Efstathiou, J.W. Davis, L. Pisters, W. Li, S. Wen, R.P. McMullin, M. Gormley, D. Ricci, M. Titus, A. Hoang, A.J. Zurita, N. Tran, W. Peng, T. Kheoh, A. Molina, P. Troncoso, C.J. Logothetis</i> Neoadjuvant therapy with abiraterone acetate + prednisone (AAP) + luteinising hormone-releasing hormone agonist (LHRHa) induced significant cytoreduction associated with a lack of recurrence versus LHRHa, though staging did not differ significantly. This first randomised AAP study in localised high-risk prostate cancer explores response heterogeneity and associated molecular effects to guide further research.	418
	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect <i>F. Pederzoli, M. Bandini, A. Briganti, E.R. Plimack, G. Niegisch, E.Y. Yu, A. Bamias, N. Agarwal, S.S. Sridhar, C.N. Sternberg, U.N. Vaishampayan, C. Théodore, J.E. Rosenberg, L.C. Harshman, J. Bellmunt, M.D. Galsky, A. Gallina, A. Salonia, F. Montorsi, A. Necchi</i> Adjuvant chemotherapy after neoadjuvant treatment and radical cystectomy for muscle-invasive bladder cancer should be offered only to patients with a high risk of 1-yr recurrence. Time-based endpoints may be more useful to help data interpretation for the next adjuvant and neoadjuvant immunotherapy studies.	 425
Platinum Priorities Brief Correspondence and Original Articles together with the Full Length Editorials	Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells <i>K. Kettunen, P.J. Boström, T. Lamminen, T. Heinosalo, G. West, I. Saarinen, K. Kaipio, J. Rantala, C. Albanese, M. Poutanen, P. Taimen</i> Conditional reprogramming will help to recapitulate the characteristics of bladder cancer tumor ex vivo and test their drug sensitivity and resistance. This could aid in defining effective therapeutic options on an individual patient basis.	 430
	Conditionally Reprogrammed Patient-derived Cells: A Step Forward Towards Personalized Medicine? <i>A. Martini, J.P. Sfakianos, M.D. Galsky</i>	435
Bladder Cancer		

Kidney Cancer



Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME) EU*ACME 437

R.E. De Bruijn, P. Mulders, M.A. Jewett, J. Wagstaff, J.V. Van Thienen, C.U. Blank, R. Van Velthoven, L. Wood, H.E. van Melick, M.J. Aarts, J.B. Lattouf, T. Powles, I.J. De Jong, S. Rottey, B. Tombal, S. Marreaud, S. Collette, L. Collette, J.B. Haanen, A. Bex

The sequence of targeted therapy does not affect surgical safety in metastatic renal cell cancer.

Surgical Safety of Cytoreductive Nephrectomy Following Systemic Therapy: What Should We Look For? 441

U. Capitanio, F. Montorsi, A. Larcher

Prostate Cancer



Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study 443

N. Fossati, D. Robesti, R. Jeffrey Karnes, M. Soligo, S.A. Boorjian, A. Bossi, G. Coraggio, N. Di Muzio, C. Cozzarini, B.N. Chiorda, G. Gandaglia, S. Scarcella, D. Bartkowiak, D. Böhmer, S. Shariat, V. Fonteyne, P. Ost, H. Van Poppel, F. Montorsi, T. Wiegel, A. Briganti

The oncological benefit of hormonal therapy (HT) duration among men receiving salvage radiation therapy for increasing prostate-specific antigen after radical prostatectomy depends on their clinical and pathological characteristics. Our data suggest a significant effect of long-term HT for patients with two or more adverse features. Conversely, short-term HT was sufficient for patients with a single risk factor, whereas patients without any risk factors did not show a significant benefit from concomitant HT.

Androgen Deprivation Therapy with Postprostatectomy Radiotherapy: For Whom and for How Long? 450

C. Dearman, C. Parker

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring *BRCA1* or *BRCA2* Versus *ATM* Mutations 452

C.H. Marshall, A.O. Sokolova, A.L. McNatty, H.H. Cheng, M.A. Eisenberger, A.H. Bryce, M.T. Schweizer, E.S. Antonarakis

In this retrospective review of 23 patients with *BRCA1/2* or *ATM* mutations treated with olaparib, we found that none of six men with *ATM* mutations achieved a 50% decline in prostate-specific antigen, compared to 13/17 men with *BRCA1/2* mutations. Patients with *BRCA1/2* mutations also had longer progression-free survival on olaparib treatment. Men with metastatic castration-resistant prostate cancer harboring *ATM* mutations may not respond to PARP inhibitors as well as men with *BRCA1/2* mutations and may require alternative therapies.

PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers 459

J. Mateo, S. Carreira, J.S. de Bono

The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS) 461

O. Bratt, E. Holmberg, O. Andrén, S. Carlsson, L. Drevin, E. Johansson, A. Josefsson, M. Nyberg, J. Sandberg, P. Stattin, D. Robnsson

Anteriorly directed transrectal biopsy cores often detect Gleason grade group ≥ 2 cancer in men with a high prostate-specific antigen density who start on active surveillance for low-risk prostate cancer.

Overactive Surveillance: Is "Conservative" Management for Low-risk Prostate Cancer Too Aggressive? 467

S. Loeb

Pediatric Urology



Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer 469

A. Paschalis, B. Sheehan, R. Riisnaes, D.N. Rodrigues, B. Gurel, C. Bertan, A. Ferreira, M.B.K. Lambros, G. Seed, W. Yuan, D. Dolling, J.C. Welti, A. Neeb, S. Sumanasuriya, P. Rescigno, D. Bianchini, N. Tunariu, S. Carreira, A. Sharp, W. Oyen, J.S. de Bono

Membranous prostate-specific membrane antigen (mPSMA) expression is upregulated in many, but not all, prostate cancers. Importantly, prostate-specific membrane antigen (PSMA) expression demonstrates marked intra- and interpatient heterogeneity, limiting the clinical utility of PSMA theranostics. Defective DNA repair gene aberrations are associated with significantly higher mPSMA expression levels in metastatic castration-resistant prostate cancer and may serve as predictive biomarkers for PSMA-targeted therapies.

Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength? 479

M.S. Hofman, L. Emmett

Hypospadias Prevalence and Trends in International Birth Defect Surveillance Systems, 1980–2010 482

X. Yu, N. Nassar, P. Mastroiacovo, M. Canfield, B. Groisman, E. Bermejo-Sánchez, A. Ritvanen, S. Kiuru-Kuhlefelt, A. Benavides, A. Sipek, A. Pierini, F. Bianchi, K. Källén, M. Gatt, M. Morgan, D. Tucker, M.A. Canessa, R. Gajardo, O.M. Mutchinick, E. Szabova, M. Csáky-Szunyogh, G. Tagliabue, J.D. Cragan, W.N. Nembhard, A. Rissmann, D. Goetz, C. Bower, G. Baynam, R.B. Lowry, J.A. Leon, W. Luo, J. Rouleau, I. Zarante, N. Fernandez, E. Amar, S. Dastgiri, P. Contiero, L.E. Martínez-de-Villarreal, B. Borman, J.E.H. Bergman, H.E.K. de Walle, C.A. Hobbs, A.E. Nance, A.J. Agopian

We report on prevalence and trends of hypospadias among 27 birth defect surveillance systems (1980–2010), which indicate that the prevalence of hypospadias continues to increase internationally.

Hypospadias increased prevalence in Surveillance Systems for Birth Defects is observed: Next to climate change are we going towards a human fertility alteration? 491

A.-F. Spinoit

Review



Prostate Cancer

Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review 493

G. Ploussard, G. Gandaglia, H. Borgmann, P. de Visschere, I. Heidegger, A. Kretschmer, R. Mathieu, C. Surcel, D. Tilki, I. Tsaur, M. Valerio, R. van den Bergh, P. Ost, A. Briganti

Salvage lymph node dissection in the setting of radiological node-only recurrence after primary prostate cancer treatment is associated with promising early oncological outcomes in terms of prostate-specific antigen response, and the safety profile is acceptable. Long-term comparative studies are awaited.

Surgery in Motion



Three-dimensional Elastic Augmented-reality Robot-assisted Radical Prostatectomy Using Hyperaccuracy Three-dimensional Reconstruction Technology: A Step Further in the Identification of Capsular Involvement 505

F. Porpiglia, E. Checcucci, D. Amparore, M. Manfredi, F. Massa, P. Piazzolla, D. Manfrin, A. Piana, D. Tota, E. Bollito, C. Fiori

With the elastic three-dimensional augmented-reality robot-assisted radical prostatectomy, prostate deformation is correctly simulated during surgery and the lesion is correctly identified, allowing optimization of the nerve-sparing tailoring with a potential reduction of positive surgical margin rate and possible maximization of the functional outcomes.

Three-dimensional Elastic Augmented Reality for Robot-assisted Laparoscopic Prostatectomy: Pushing the Boundaries, but Cutting it Fine 515

M. Pokorny, J. Yaxley

Original Articles		<p>Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer 517</p> <p><i>T. Horn, M. Krönke, I. Rauscher, B. Haller, S. Robu, H.-J. Wester, M. Schottelius, F.W.B. van Leeuwen, H.G. van der Poel, M. Heck, J.E. Gschwend, W. Weber, M. Eiber, T. Maurer</i></p> <p>Prostate-specific membrane antigen (PSMA) radioguided surgery leads to a substantial prostate-specific antigen (PSA) reduction in the vast majority of patients with recurrent prostate cancer. A low PSA value and the presence of only one lesion on preoperative imaging with PSMA-ligand positron emission tomography are prognostic factors for a better outcome.</p>
Prostate Cancer		<p>Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer 524</p> <p><i>E. Feld, J. Harton, N.J. Meropol, B.J.S. Adamson, A. Cohen, R.B. Parikh, M.D. Galsky, V. Narayan, J. Christodouleas, D.J. Vaughn, R.A. Hubbard, R. Mamtani</i></p> <p>For cisplatin-ineligible metastatic urothelial carcinoma patients, we compared overall survival (OS) with first-line carboplatin-based chemotherapy versus immunotherapy. Immunotherapy demonstrated inferior 12-mo OS relative to carboplatin-based chemotherapy, but superior OS beyond 12 mo. Early benefits of chemotherapy must be balanced against late benefits of immunotherapy.</p>
Bladder Cancer		<p>Re: Long-term Rate of Mesh Sling Removal Following Midurethral Mesh Sling Insertion Among Women with Stress Urinary Incontinence 533</p> <p><i>J.P.F.A. Heesakkers</i></p> <p>Re: Use of Prostate Systematic and Targeted Biopsy on the Basis of Multiparametric MRI in Biopsy-naïve Patients (MRI-FIRST): A Prospective, Multicentre, Paired Diagnostic Study 534</p> <p><i>S.V. Carlsson, J.A. Eastham</i></p> <p>Re: Optimizing Patient's Selection for Prostate Biopsy: A Single Institution Experience with Multi-parametric MRI and the 4Kscore Test for the Detection of Aggressive Prostate Cancer 535</p> <p><i>D. Margel, Y. Ber, J. Baniel</i></p> <p>Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer 536</p> <p><i>O. Alghazo, I. Thangasamy, N. Sathianathan, D.G. Murphy</i></p> <p>Re: Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone 537</p> <p><i>G. Devos, G. De Meerleer, C. Berghen, S. Joniau</i></p> <p>Re: Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial 538</p> <p><i>B. Hadaschik, P. Ost</i></p>
Words of Wisdom		<p>Re: Dan Wood, Andrew Baird, Luca Carmignani, et al. Lifelong Congenital Urology: The Challenges for Patients and Surgeons. Eur Urol 2019;75:1001-7 e93</p> <p><i>C. Cheng, S. Ma, Y. Liu</i></p> <p>Reply to Chen Cheng, Sunxiang Ma, and Yang Liu's Letter to the Editor re: Dan Wood, Andrew Baird, Luca Carmignani, et al. Lifelong Congenital Urology: The Challenges for Patients and Surgeons. Eur Urol 2019;75:1001-7 e94</p> <p><i>D. Wood, A. Baird, L. Carmignani, G. De Win, P. Hoebeke, G. Holmdahl, G. Manzoni, R.J.M. Nijman, C. Taylor, S. Tekgul</i></p> <p>Re: Philip S. Macklin, Mark E. Sullivan, Charles R. Tapping, et al. Tumour Seeding in the Tract of Percutaneous Renal Tumour Biopsy: A Report on Seven Cases from a UK Tertiary Referral Centre. Eur Urol 2019;75:861-7 e96</p> <p><i>M. Hora</i></p>
Letters to the Editor published online		

<p>Reply to Milan Hora's Letter to the Editor re: Philip S. Macklin, Mark E. Sullivan, Charles R. Tapping, et al. Tumour Seeding in the Tract of Percutaneous Renal Tumour Biopsy: A Report on Seven Cases from a UK Tertiary Referral Centre. Eur Urol 2019;75:861–7</p> <p><i>P.S. Macklin, M.E. Sullivan, C.R. Tapping, G.M. Webster, I.S.D. Roberts, C.L. Verrill, L. Browning</i></p> <p>Re: Jacob A. Burns, Adam B. Weiner, William J. Catalone, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846–52</p> <p><i>Z.G. Gul, A. Martini, C.A. Olsson</i></p> <p>Reply to Zeynep G. Gul, Alberto Martini, and Carl A. Olsson's Letter to the Editor re: Jacob A. Burns, Adam B. Weiner, William J. Catalone, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846–52</p> <p><i>J.A. Burns, A.B. Weiner, S. Kundu</i></p> <p>Re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548–51</p> <p><i>P.R. Dirix, C. Mercier, L.Y. Dirix</i></p> <p>Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548–51</p> <p><i>T. Hölscher, F. Lohaus, M. Wirth, E.G.C. Troost</i></p> <p>Re: Benoit Peyronnet, Emma Mironska, Christopher Chapple, et al. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol 2019;75:988–1000. Overactive Bladder Symptoms Can Be Caused by Pelvic Organ Prolapse</p> <p><i>B. Liedl, K. Goeschen, F. Wagenlehner</i></p> <p>Reply to Bernhard Liedl, Klaus Goeschen, and Florian Wagenlehner's Letter to the Editor re: Benoit Peyronnet, Emma Mironska, Christopher Chapple, et al. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol 2019, 75:988–1000</p> <p><i>B. Peyronnet, C. Chapple, J.-N. Cornu</i></p> <p>Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.</p> <p><i>J. Liang, J.M. Beckta, R.S. Bindra</i></p> <p>Re: F. Johannes P. van Valenberg, Andrew M. Hiar, Ellen Wallace, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. 2019; 75,5: 853-860</p> <p><i>L. Cao, Z. Yang, B. Wang</i></p>	<p>e97</p> <p>e98</p> <p>e99</p> <p>e101</p> <p>e103</p> <p>e105</p> <p>e107</p> <p>e109</p> <p>e111</p> <hr/> <p>Congress Calendar</p> <hr/> <p>e113</p>
---	--

The illustration on the cover of this issue is taken from the article by Francesco Porpiglia, Enrico Checcucci, Daniele Amparore, Matteo Manfredi, Federica Massa, Pietro Piazzolla, Diego Manfrin, Alberto Piana, Daniele Tota, Enrico Bollito, Cristian Fiori, Three-dimensional Elastic Augmented-reality Robot-assisted Radical Prostatectomy Using Hyperaccuracy Three-dimensional Reconstruction Technology: A Step Further in the Identification of Capsular Involvement, which is published on pp. 505–514 of this issue.

